Treatment for Subjects With Unresectable Stage III or Stage IV Melanoma

Inclusion Criteria:

Patients who have a life expectancy of at least 12 weeks
Patients with histologically or cytologically confirmed unresectable (Stage III) or metastatic (Stage IV) melanoma
Patients who have an ECOG PS of 0, or 1
Measurable disease defined as at least one lesion that can be accurately and serially measured per the modified RECIST criteria

Exclusion Criteria:

Primary ocular or mucosal melanoma
Previous or concurrent cancer that is distinct in primary site or histology from the cancer being evaluated in this study except cervical carcinoma in situ, treated basal cell carcinoma, superficial bladder tumors (Ta [Noninvasive papillary carcinoma], Tis [Carcinoma in situ: "flat tumor"] & T1 [Tumor invades subepithelial connective tissue]) or any cancer curatively treated < 3 years prior to study entry
History of cardiac disease
Known history of human immunodeficiency virus (HIV) infection